Amotz Shemi, PhD


Dr. Shemi is a co-founder of Silenseed and has served as the company’s Chief Executive Officer since its incorporation in 2008. Prior to founding Silenseed, from 2005 to 2008 Dr. Shemi served as the Senior Vice President Technologies at Medinol Ltd., a world leader in design, development and manufacturing of stent and stent delivery systems. Prior to that time Dr. Shemi was the chief executive of several private Israeli technology companies including Color-Chip Ltd. Dr. Shemi holds a Ph.D. degree in Physics from the Tel Aviv University. He is a single author and co-author of many scientific papers and a single inventor and co-inventor of about a dozen of patents.

Eran Ovadya, MBA


Eran brings almost two decades of broad experience in corporate fi nance, accounting, M&Atransactions, and IPOs. He has a signifi cant expertise in public Life Science companies traded on theTASE, OTC, Nasdaq, CSE, with a professional track record from 1st tier global corporations, such as:Johnson & Johnson, West pharma, Omrix Biopharmaceuticals, Macrocure, and many other SMBscompanies.

Eran provides a CFO services through Selo Financial Services, a company which he founded andserves as Chief Executive Offi cer. Selo offers a full suite of fi nancial services in response to strongdemand from both publicly and privately held companies seeking to outsource their high-level fi nancialand accounting activities typically performed by an in-house CFO. Eran is a dynamic, innovative &results-oriented leader with diverse multinational experience, with a strong track record ofperformance in highly competitive environments and great interpersonal skills. Eran holds an MBAspecializing in Financing and BA degree in Accounting & Economics.

Ettie Pirak, PhD

Director, Drug Development

Dr. Ettie Pirak, Ph.D. is a co-inventor of a monoclonal antibody cancer therapy directed against EGFR; it includes among others that of the monoclonal antibody drug Cetuximab (Erbitux®).

Dr. Pirak has founded Innovo Biotechnologies in 1998 (DNA Vaccines). She was a Director of Research Collaboration at Compugen. Dr. Pirak served as the Vice President of Technologies at Meytav Technological Incubator. She also served as a Director in Quinova Rx, Angio B, Novotyr therapeutics and Protea. She was for ten years a Consultant for IP portfolio and projects development at Yissum, the technology transfer company of the Hebrew University of Jerusalem.  Dr. Pirak is a member of the International Board of the Weizmann Institute of Science for a three-year term. She holds a Ph.D. from the Faculty of Chemistry, University of Louvain la Neuve, Belgium.

Revital Maor-Aloni, PhD

Vice President Quality

Dr. Maor-Aloni is a Senior Manager, highly experienced in the biotech, pharma and medical device industries combined with extensive experience in leading quality processes for compliance with FDA regulations, ICH, CFR, Medical Device Directive 93/42/EEC, ISO (including ISO 17025, ISO 13485), Eudralex, cGMP, GLP and IMOH guidelines. She is experienced in leading company quality strategies based on risk management as well as leading process and product control strategies.
She is supervised all quality aspects QA, QC and validation as well as orchestrated CMC activities and overseen risk management and assessments, policies, procedures and guidance documents, failure investigations,
quality events and CAPA, training and qualification, supplier quality and more.
Revital holds a PhD in Microbiology and Immunology from Ben-Gurion University, and a Post-Doctorate in Molecular Biology from Weizmann Institute of Science.

Eran Gefen, M.D

Chief medical officer

Seasoned med-tech executive and physician with more than 15 years of experience in the life sciences industry, including positions in start-up, medium sized-biotech and large pharma; specialized in brining drugs from clinical development to market. Eran is a versatile leader and contributor with experience in varied domains including clinical R&D, regulatory strategy, Medical Affairs, life-cycle management & evidence generation and business development. 

Eran is currently employed at Teva pharmaceuticals as VP, Head of Medical Affairs International Markets where he is accountable for International Markets (APAC, Japan, LatAm, EEMEA & Oceania) Medical Affairs strategies, plans, execution and governance. Eran’s professional objective is to drive scientific & medical strategies poised for significant revenue results.